Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 21 to 30 of 604 total matches.

Addendum: Drugs for Depression

   
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024  (Issue 1695)
Addendum: Drugs for Depression ...
In our article on Drugs for Depression, we should have included tardive dyskinesia (TD) in our list of adverse effects of second-generation antipsychotic (SGA) drugs. TD, which is more commonly associated with first-generation- antipsychotics, can also occur in patients taking an SGA, especially with prolonged use. A metaanalysis found that the annualized incidence of TD was 2.6% in SGA users (M Carbon et al. World Psychiatry 2018; 17:330). Older adults are at increased risk.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):24   doi:10.58347/tml.2024.1695e |  Show IntroductionHide Introduction

Drugs for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024  (Issue 1706)
Drugs for Postmenopausal Osteoporosis ...
Pharmacologic treatment is recommended for postmenopausal women who have bone density T-scores (standard deviations from normal mean values in the spine, femoral neck, total hip, or distal radius) of -2.5 or below, T-scores between -1.0 and -2.5 with a history of fragility (low-trauma) fracture of the hip or spine, or T-scores between -1.0 and -2.5 with a FRAX 10-year probability of ≥3% for hip fracture or ≥20% for major osteoporotic fracture.
Med Lett Drugs Ther. 2024 Jul 8;66(1706):105-12   doi:10.58347/tml.2024.1706a |  Show IntroductionHide Introduction

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024  (Issue 1697)
Drugs for Menopausal Symptoms ...
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8   doi:10.58347/tml.2024.1697a |  Show IntroductionHide Introduction

Drugs for Head Lice

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024  (Issue 1704)
Drugs for Head Lice ...
Pediculosis capitis (head lice infestations) occur in all age groups, but especially in elementary school children. In most cases, transmission occurs by head-to-head contact. Pharmacologic treatment is recommended for persons with live lice or eggs (nits) within 1 cm of the scalp. Topical pediculicides should be tried first. Oral therapy is occasionally required for refractory infestations.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):89-92   doi:10.58347/tml.2024.1704a |  Show IntroductionHide Introduction

Table: Some Drug Interactions with Drugs for IBD (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
Table: Some Drug Interactions with Drugs for IBD (online only) ...
View the Table: Some Drug Interactions with Drugs for IBD
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e114   doi:10.58347/tml.2023.1680c |  Show IntroductionHide Introduction

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
Drugs for Opioid Use Disorder ...
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44   doi:10.58347/tml.2023.1684a |  Show IntroductionHide Introduction

Drugs and Devices for Weight Management

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025  (Issue 1734)
Drugs and Devices for Weight Management ...
Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI, a 5-10% reduction in weight has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the traditional methods for losing weight, but they are often inadequate; the American College of Cardiology no longer recommends that all patients try lifestyle modification alone before adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8   doi:10.58347/tml.2025.1734a |  Show IntroductionHide Introduction

Drugs for Cognitive Loss and Dementia

   
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022  (Issue 1657)
Drugs for Cognitive Loss and Dementia ...
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
Med Lett Drugs Ther. 2022 Aug 22;64(1657):129-36 |  Show IntroductionHide Introduction

Drugs for Irritable Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
Drugs for Irritable Bowel Syndrome ...
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating. IBS is classified by its predominant bowel symptom: constipation (IBS-C), diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Since the exact cause of IBS is unknown, the goal of treatment is symptom control. Some over-the-counter (OTC) products and prescription drugs for IBS are listed in Tables 1-4. The safety of these drugs during pregnancy and lactation is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24   doi:10.58347/tml.2025.1721a |  Show IntroductionHide Introduction

Drugs for Benign Prostatic Hyperplasia

   
The Medical Letter on Drugs and Therapeutics • May 02, 2022  (Issue 1649)
Drugs for Benign Prostatic Hyperplasia ...
About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent disease progression and complications such as acute urinary retention. The American Urologic Association's guidelines for treatment of BPH were recently updated.
Med Lett Drugs Ther. 2022 May 2;64(1649):65-9 |  Show IntroductionHide Introduction